A down round prices new shares below the prior round's price per share, typically triggering anti-dilution adjustments and signaling that the company has missed expectations. Down rounds can trigger anti-dilution adjustments, reduce employee option value and require consent of existing preferred holders. Companies sometimes pair them with recapitalizations or pay-to-play terms. Boards need careful process, often including a rights offering, to reduce fiduciary risk.

Why it matters

MedTech down rounds frequently follow failed pivotal trials, FDA non-clearances, or post-market safety signals. A well-structured 'pay-to-play' can keep insiders engaged and prevent worst-case dilution math.

Common pitfalls

•Failing to understand that a down round often signals underlying issues in regulatory strategy, quality management, or product development lifecycle.
•Assuming that financial remedies like "pay-to-play" provisions negate the need for addressing the root causes related to regulatory non-compliance or product quality.
•Neglecting to perform a thorough post-market surveillance and corrective and preventive action (CAPA) process after a significant product issue, which could lead to a down round.
•Underestimating the impact of regulatory non-compliance fines or market withdrawals, which can be precursors to a down round, on investor confidence.
•Not recognizing that repeated down rounds can indicate systemic problems in a company's ability to meet regulatory milestones or product performance expectations.

Sources

Cooley GO: down rounds · Cooley GO
NVCA Model Documents · NVCA
Silicon Valley Bank - Healthcare Reports · SVB
FASB ASU 2017-11: down-round price-adjustment features (accounting context) · Financial Accounting Standards Board, 13 July 2017 news release on ASU 2017-11

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.